ALung Technologies, Inc.
ALung has developed the Hemolung™, an extracorporeal artificial lung that will replace or supplement the ventilator in the ICU for acute respiratory failure. The Hemolung will provide 50% of a patient’s respiratory need, allowing the lungs to heal, eliminating the need for intubation, sedation and mechanical ventilation. The Hemolung™ will reduce the incidence of ventilator associated pneumonia and hospital length of stay, resulting in a reduced cost of care for these patients. The Company has completed animal and human trials and expects initiate commercialization in Europe in Q1 2013.
Acquired by London based Liva-Nova.